# EsoBiotec

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/esobiotec

- Industry: Biotechnology
- Headquarters: Belgium
- Website: www.esobiotec.com
- Total disclosed funding: $3.9M
- Latest round: Series A (Dec 11, 2023)
- Investors on record: 4

## About

Based in Belgium, and founded in 2020, EsoBiotec operates as a biotechnology company that offers gene therapy solutions for cancer treatment. The company was founded by its CEO, Jean-Pierre Latere. In September 2021, EsoBiotec raised EUR 6 million in venture funding from Thuja Capital, SRIW, and Sambrinvest.

EsoBiotec offers biotech research solutions, including the development and commercialization of therapeutic products such as cell therapy and cancer therapies for the medical sector. The company uses in vivo-engineered CAR-T cells and genetic material to create therapies that target specific types of cancer cells. The firm provides off-the-shelf therapeutics for the treatment of cancer.

## Funding rounds

- Series A, Dec 11, 2023, $2.1M — Invivo Partners
- Seed, Oct 11, 2021, $1.7M — Thuja Capital, Sambrinvest, Wallonie Entreprendre

## Investors

- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Seed
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Seed
- Wallonie Entreprendre — Seed
- Invivo Partners (https://capitalatlas.ai/funds/invivo-partners) — Series A